Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): Y. Nakamura, T. Esaki, T. Nishina, E. Shinozaki, H. Taniguchi, T. Kato, Y. Komatsu, S. Yuki, K. Kato, M. Wakabayashi, T. Ikeno, Y. Ishiguro, K. Takahashi, Y. Ikeda, M. Asano, A. Sato, T. Kuwata, T. Yoshino
Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial. // ESMO Open. – URL: https://www.sciencedirect.com/science/article/pii/S2059702926025238?dgcid=rss_sd_all
Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial. ESMO Open. https://www.sciencedirect.com/science/article/pii/S2059702926025238?dgcid=rss_sd_all
“Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial.” ESMO Open.
@article{article93746,
title = {Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial},
journal = {ESMO Open},
url = {https://www.sciencedirect.com/science/article/pii/S2059702926025238?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment